Nordisk

Analyst Recommendations: Keep an eye on financial analysts’ reports and recommendations regarding Novo Nordisk’s stock.

APAICS lists Novo Nordisk as a partner on webpages for events in March and May where panel discussions touched on the treatment of obesity.

Because Wegovy is not yet available in Canada — and Novo Nordisk has not given a date when it will be — some doctors are prescribing Ozempic at higher doses for their patients suffering from obesity.

BlackRock Inc. boosted its stake in Novo Nordisk A/S by 45.4% in the 1st quarter.

By expanding its manufacturing capacity, Lilly could avoid some of the manufacturing constraints that encountered by rival Novo Nordisk and its weight loss drug, Wegovy.

Comerica Bank trimmed its stake in shares of Novo Nordisk A/S () by 4.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.

Dynamic Advisor Solutions LLC’s holdings in Novo Nordisk A/S were worth $2,667,000 as of its most recent SEC filing.

Juleen Zierath funding from the Swedish Research Council, Swedish Diabetes Foundation, Swedish Research Council for Sport Science and Novo Nordisk Foundation.

Manufactured by the Danish firm Novo Nordisk, the drug was initially developed to treat type 2 diabetes in 2012.

Novo Nordisk chose to ramp up production before making it available in Britain, with labs working 24/7.

Novo Nordisk credited this rise - up by a third, or £1.3billion, on the previous spell - to the sky-high demand for its weekly semaglutide jabs.

Novo Nordisk (NVO) shares are surging, up 51% in 2023.

Novo Nordisk plans to invest €2.1bn to expand production in France as it works to meet surging demand for its sought-after weight-loss medicines.

Novo Nordisk’s German Wegovy launch might take a while to succeed.

Novo Nordisk’s Ozempic and Lilly’s Mounjaro, given as once-weekly injections, helps lower diabetes as well aids in weight loss.

Novo Nordisk’s shares on the news.

Novo Nordisk's stock price kept climbing in European trading on Tuesday morning after the Danish drugmaker dethroned French LVMH (Louis Vuitton Moet Hennessy) as the continent's most valuable company, based on its market capitalisation.

Ozempic is a brand-name diabetes medication manufactured by Novo Nordisk, but the medical ingredient in it is called semaglutide.

Sell-side analysts expect that Novo Nordisk A/S will post 2.61 earnings per share for the current year.

The success of these treatments, especially from companies such as Novo Nordisk and Eli Lilly, has attracted the attention of celebrities, including Tesla chief executive Elon Musk and former British prime minister Boris Johnson.